Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Lynch syndrome (also sometimes called hereditary nonpolyposis colorectal cancer, or HNPCC) is hereditary and affects 1 in 500-1,000 people. Inherited mutations in the MLH1, MSH2, MSH6, PMS2 genes, or certain mutations in the EPCAM gene, are associated with
Increased cancer risks associated with
Lynch syndrome include:
The exact increase in risk for each cancer depends upon which of the Lynch syndrome-associated genes mutations runs in the family, and recommendations for surveillance and risk reduction should be tailored to the gene involved. Which
Lynch syndrome mutations may be associated with an increased risk of breast cancer remains unclear. Research in this area is ongoing.
Clinical guidelines have been established for managing cancer risk in people with
Lynch syndrome. Management options depend upon the specific inherited mutation that is associated with Lynch syndrome. FORCE recommends consulting with a genetics expert to understand your exact risk and risk management options.